This first randomized clinical study of a polymer-coated zotarolimus-eluting stent (Resolute Onyx) that utilizes a novel thin-strutted metallic platform allowing for better X-ray visibility was shown to be non-inferior to ...
Sep 24, 2018
0
0
Results from the prospective, multicenter, randomized investigator-initiated REDUCE trial were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular ...
Nov 2, 2017
0
0
A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI) are at a greater risk of experiencing recurrent cardiac events within the first year after their procedure ...
May 12, 2017
0
1
(HealthDay)—For patients with stable angina (SA) or acute coronary syndrome (ACS), the benefits and risks of cangrelor are consistent, according to a study published in the Sept. 26 issue of JACC: Cardiovascular Interventions.
Oct 4, 2016
0
0
(HealthDay)—The American College of Cardiology and the American Heart Association Task Force on Clinical Practice Guidelines has updated the recommendations regarding duration of dual antiplatelet therapy (DAPT) for patients ...
Mar 31, 2016
0
0
Percutaneous coronary intervention (PCI) is a staple of modern day medicine in which cardiologists place a stent in a blood vessel around the heart in order to restore blood flow in people with heart disease. Blood thinners ...
Jan 14, 2016
0
0
(HealthDay)—Routine use of dual antiplatelet therapy (DAPT) beyond six months after second generation drug-eluting stent (DES) implantation yields mixed clinical results, according to a review published in the October issue ...
Oct 1, 2015
0
6
Extending treatment with the anticoagulant bivalirudin for at least four hours after completion of percutaneous coronary intervention (PCI) does not improve outcomes compared to stopping the treatment immediately after the ...
Sep 1, 2015
0
10
Recruitment of leukocytes is a hallmark of stent thrombosis, according to results from the PRESTIGE study presented today at ESC Congress and published in European Heart Journal. The findings suggest that immune cell mediated ...
Aug 31, 2015
0
6
A costly drug frequently used to treat patients with heart disease may offer no greater benefit than standard medications, say Yale researchers. Their study calls into question widespread use of the drug bivalirudin (Angiomax) ...
Jun 25, 2015
0
6
